Trial record 2 of 6 for:    nestorone

NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel (NES-1)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
John Amory, University of Washington
ClinicalTrials.gov Identifier:
NCT00229593
First received: September 27, 2005
Last updated: September 9, 2013
Last verified: September 2013

September 27, 2005
September 9, 2013
September 2005
January 2007   (final data collection date for primary outcome measure)
- To determine the gonadotropin suppressive activity of Nestorone (NES) Gel at two doses and T gel at one dose alone or in combination over a 3-week period. Serum levels of gonadotropins will be assessed in all subjects. [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
- To determine the gonadotropin suppressive activity of NES at two doses and T gel at one dose alone or in combination over a 3-week period. Serum levels of gonadotropins will be assessed in all subjects.
Complete list of historical versions of study NCT00229593 on ClinicalTrials.gov Archive Site
  • To determine the effects on serum levels of total and free testosterone and SHBG and measure serum levels of NES gel. [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
  • Safety measured laboratory evaluations, vitals, pre- and post treatment physical exam results and PSA levels [ Time Frame: 3 weeks ] [ Designated as safety issue: Yes ]
  • - To determine the effects on serum levels of total and free testosterone and SHBG and measure serum levels of NES gel.
  • - Safety measured laboratory evaluations, vitals, pre- and post treatment physical exam results and PSA levels
Not Provided
Not Provided
 
NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel
A Randomized, Open Label Clinical Trial to Evaluate if Nestorone Gel Has Gonadotropin Suppressive Activity and if Nestorone in Combination With Testosterone Will Have an Additive Effect on Gonadotropin Suppression When Applied Transdermally in Healthy Men

The purpose of this study is to determine the usefulness of two transdermal gels to be used in the future development for a male contraceptive.

The success of hormonal male contraception depends on the near complete suppression of spermatogenesis without producing any untoward effects on libido or other androgen-dependent functions or any other adverse events. The treatment with androgen alone has geen shown to be highly effective in Asian men but less effective in non-Asian men in clinical trials. To increase the efficacy of androgen alone treatment on spermatogenesis, combined regimens of a progestin and an androgen have shown promising results. The steady-state delivery of a progestin and an androgen by transdermal gel application would be a user-friendly delivery method as compared to injectable or implant approaches. Nestorone (NES) is a synthetic progestin that does not have any androgenic and estrogenic activity and is not expected to have some of the undesirable side effects of other drugs.

We propose to evaluate whether NES gel alone or in combination with T gel applied transdermally will result in more effective suppression of gonadotropins than NES or T gel applied alone in healthy men. Fifty healthy male subjects, age 18-50 will be enrolled at each center (2 sites).

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Contraception
  • Drug: Nestorone gel
    2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
  • Drug: Testosterone Gel
    100 mg Testosterone gel daily for 3 weeks
    Other Name: Testim
  • Active Comparator: 1
    100 mg Testosterone gel daily for 3 weeks
    Intervention: Drug: Testosterone Gel
  • Active Comparator: 2
    2 mg Nestorone gel daily for 3 weeks
    Intervention: Drug: Nestorone gel
  • Active Comparator: 3
    4 mg Nestorone gel daily for 3 weeks
    Intervention: Drug: Nestorone gel
  • Active Comparator: 4
    100 mg Testosterone gel + 2 mg Nestorone gel
    Interventions:
    • Drug: Nestorone gel
    • Drug: Testosterone Gel
  • Active Comparator: 5
    100 mg Testosterone gel + 4 mg Nestorone gel
    Interventions:
    • Drug: Nestorone gel
    • Drug: Testosterone Gel
  • Active Comparator: 6
    100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks
    Interventions:
    • Drug: Nestorone gel
    • Drug: Testosterone Gel
  • Active Comparator: 7
    100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks
    Interventions:
    • Drug: Nestorone gel
    • Drug: Testosterone Gel

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
140
January 2007
January 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy men
  • Aged 18-50 years
  • With normal clinical chemistry, serum levels of testosterone, PSA, gonadotropins within normal limits, and sperm concentration greater than 20 million/mL
  • Subject or his partner willing to use a recognized effective method of contraception

Exclusion Criteria:

  • Men not living in area of clinics
  • Clinically significant abnormal findings at screening
  • Elevated PSA greater than 4
  • Partners who are pregnant
  • Abnormal laboratory values, liver or kidney dysfunction
  • Sperm counts below 20 million/mL.
  • Use of androgens or body building substances within 6 months of enrollment,
  • Blood pressure greater than 140/90, history of hypertension, including hypertension controlled with treatment
  • History of primary testicular disease or disorder of the hypothalamic-pituitary axis
  • Hypersensitivity of progestins
  • History of venous thromboembolism
  • Benign or malignant liver tumors
  • Active liver disease, history of reproductive dysfunction including vasectomy or infertility
  • History of active or chronic cardiac, renal, hepatic or prostatic disease
  • Diabetes mellitus or morbid obesity (body weight greater than 120% of ideal body weight)
  • Known or suspected alcoholism or drug abuse
  • Known dermatitis or severe skin disorder

Men desiring fertility within 6 months or participating in competitive sports where drug screening for prohibited substances (including anabolic steroids) is routine will be advised of the relative and temporary hazards that participating in this study may have for their fertility or sporting status.

Male
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00229593
26852-D, HHSN27500002;, 04-3792-D 02
Yes
John Amory, University of Washington
University of Washington
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigator: William J Bremner, MD, PhD University of Washington
Principal Investigator: Christina Wang, MD University of California, Los Angeles
University of Washington
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP